357P ADJUBIL: A phase II study of durvalumab and tremelimumab with or without capecitabine in ADJUvant BILiary tract cancer: The IKF/AIO-ADJUBIL trial
Title:
357P ADJUBIL: A phase II study of durvalumab and tremelimumab with or without capecitabine in ADJUvant BILiary tract cancer: The IKF/AIO-ADJUBIL trial
Author:
Goetze, T.O. Vogel, A. Gonzalez Carmona, M.A. Habibzade, T. Reinecke, J. Adler, M. Pink, D. Ettrich, T.J. Roderburg, C. Pession, U. Saborowski, A. Van Bömmel, F. Wehler, T.C. Koehne, C-H. Schaaf, M. Sookthai, D. Eickhoff, R. Pons, M. Al-Batran, S-E. Modest, D.P.